Geron Corporation and Amphastar Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis

Biotech Revenue Trends: Amphastar vs. Geron (2014-2023)

__timestamp	Amphastar Pharmaceuticals, Inc.	Geron Corporation
Wednesday, January 1, 2014	210461000	1153000
Thursday, January 1, 2015	251519000	36371000
Friday, January 1, 2016	255165000	6162000
Sunday, January 1, 2017	240175000	1065000
Monday, January 1, 2018	294666000	1066000
Tuesday, January 1, 2019	322357000	460000
Wednesday, January 1, 2020	349846000	253000
Friday, January 1, 2021	437768000	1393000
Saturday, January 1, 2022	498987000	596000
Sunday, January 1, 2023	644395000	237000

Unleashing the power of data

A Tale of Two Biotech Companies: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Amphastar Pharmaceuticals, Inc. has demonstrated a robust upward trajectory, with revenues surging by over 200% from 2014 to 2023. This growth reflects Amphastar's strategic market positioning and innovative product offerings. In contrast, Geron Corporation's revenue has experienced significant fluctuations, peaking in 2015 but declining sharply thereafter. By 2023, Geron's revenue had plummeted to just 6% of its 2015 peak, highlighting the challenges it faces in maintaining a steady revenue stream. This comparative analysis underscores the diverse challenges and opportunities within the biotech sector, offering valuable insights for investors and industry stakeholders.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025